These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 12503820)

  • 1. The influence of elevated liver function parameters on the pharmacokinetics of doxorubicin and epirubicin--a population based pharmacokinetic study of CESAR-APOH. Central European Society for Anticancer Drug Research. Working Group for Pharmacology in Oncology and Hematology.
    Müller HJ; Grubert M; Hilger R; Richly H; Port R; Scheulen M; Mross K;
    Int J Clin Pharmacol Ther; 2002 Dec; 40(12):575-7. PubMed ID: 12503820
    [No Abstract]   [Full Text] [Related]  

  • 2. The influence of liver metastases on the pharmacokinetics of doxorubicin---a population-based pharmacokinetic project of the CESAR-APOH.
    Müller HJ; Port RE; Grubert M; Hilger RA; Scheulen M; Mross K;
    Int J Clin Pharmacol Ther; 2003 Dec; 41(12):598-9. PubMed ID: 14692710
    [No Abstract]   [Full Text] [Related]  

  • 3. An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity.
    Prado CM; Lima IS; Baracos VE; Bies RR; McCargar LJ; Reiman T; Mackey JR; Kuzma M; Damaraju VL; Sawyer MB
    Cancer Chemother Pharmacol; 2011 Jan; 67(1):93-101. PubMed ID: 20204364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contradistinction between doxorubicin and epirubicin: in-vitro interaction with blood components.
    Ramanathan-Girish S; Boroujerdi M
    J Pharm Pharmacol; 2001 Jun; 53(6):815-21. PubMed ID: 11428657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation.
    Gurney HP; Ackland S; Gebski V; Farrell G
    J Clin Oncol; 1998 Jul; 16(7):2299-304. PubMed ID: 9667243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors.
    Tranchand B; Catimel G; Lucas C; Sarkany M; Bastian G; Evene E; Guastalla JP; Négrier S; Rebattu P; Dumortier A; Foy M; Grossin F; Mazier B; Froudarakis M; Barbet N; Clavel M; Ardiet C
    Cancer Chemother Pharmacol; 1998; 41(4):281-91. PubMed ID: 9488597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
    Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of transcatheter arterial embolization and percutaneous ethanol injection for hepatocellular carcinoma: comparison of efficacies of doxorubicin and epirubicin in transcatheter arterial embolization.
    Nakamura S; Tanaka K
    Semin Oncol; 1997 Apr; 24(2 Suppl 6):S6-46-S6-49. PubMed ID: 9151916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective and randomized trial of lipiodol-transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: a comparison of epirubicin and doxorubicin (second cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan.
    Kawai S; Tani M; Okamura J; Ogawa M; Ohashi Y; Monden M; Hayashi S; Inoue J; Kawarada Y; Kusano M; Kubo Y; Kuroda C; Sakata Y; Shimamura Y; Jinno K; Takahashi A; Takayasu K; Tamura K; Nagasue N; Nakanishi Y; Makino M; Masuzawa M; Yumoto Y; Mori T; Oda T
    Semin Oncol; 1997 Apr; 24(2 Suppl 6):S6-38-S6-45. PubMed ID: 9151915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epirubicin in a breast cancer patient with Gilbert's syndrome: apparent lack of major pharmacokinetic alterations.
    Riggi M; Poggesi I; Regazzi MB; Grasso S; Fittipaldo A; Seematter RJ
    Ann Oncol; 1999 Mar; 10(3):360-1. PubMed ID: 10355585
    [No Abstract]   [Full Text] [Related]  

  • 11. Anthracycline dose intensity: clinical pharmacology and pharmacokinetics of high-dose doxorubicin administered as a 96-hour continuous intravenous infusion.
    Synold TW; Doroshow JH
    J Infus Chemother; 1996; 6(2):69-73. PubMed ID: 8809652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors.
    Planting AS; Sonneveld P; van der Gaast A; Sparreboom A; van der Burg ME; Luyten GP; de Leeuw K; de Boer-Dennert M; Wissel PS; Jewell RC; Paul EM; Purvis NB; Verweij J
    Cancer Chemother Pharmacol; 2005 Jan; 55(1):91-9. PubMed ID: 15565444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of safety parameters and changes in serum concentration in liver transplant recipients treated with doxorubicin during the anhepatic period.
    Kobayashi S; Wada H; Hama N; Akita H; Kawamoto K; Eguchi H; Umeshita K; Doki Y; Mori M; Nagano H
    Cancer Chemother Pharmacol; 2013 Dec; 72(6):1325-33. PubMed ID: 24121480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lattice intrahepatic doxorubicin with and without in-flow occlusion: a pharmacokinetic study of direct liver injection.
    Averbach A; Stuart OA; Chang D; Sugarbaker PH
    Eur J Surg Oncol; 2000 Feb; 26(1):73-9. PubMed ID: 10718184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel.
    van Hasselt JGC; van Calsteren K; Heyns L; Han S; Mhallem Gziri M; Schellens JHM; Beijnen JH; Huitema ADR; Amant F
    Ann Oncol; 2014 Oct; 25(10):2059-2065. PubMed ID: 24713311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group.
    Bastholt L; Dalmark M; Gjedde SB; Pfeiffer P; Pedersen D; Sandberg E; Kjaer M; Mouridsen HT; Rose C; Nielsen OS; Jakobsen P; Bentzen SM
    J Clin Oncol; 1996 Apr; 14(4):1146-55. PubMed ID: 8648369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of epirubicin and doxorubicin cardiotoxicity in children and adolescents treated within the German Cooperative Soft Tissue Sarcoma Study (CWS).
    Stöhr W; Paulides M; Brecht I; Kremers A; Treuner J; Langer T; Beck JD;
    J Cancer Res Clin Oncol; 2006 Jan; 132(1):35-40. PubMed ID: 16205946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surgical management after doxorubicin and epirubicin extravasation.
    Heitmann C; Durmus C; Ingianni G
    J Hand Surg Br; 1998 Oct; 23(5):666-8. PubMed ID: 9821616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An increase of serum lipids after cumulative doses of doxorubicin and epirubicin in experimental animals.
    Stathopoulos GP; Papadopoulos NG; Stephanopoulou A; Dontas I; Kotsarelis D; Karayannacos PE
    Anticancer Res; 1996; 16(6B):3429-33. PubMed ID: 9042202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Doxorubicin pharmacokinetics: the effect of abnormal liver biochemistry tests.
    Twelves CJ; Dobbs NA; Gillies HC; James CA; Rubens RD; Harper PG
    Cancer Chemother Pharmacol; 1998; 42(3):229-34. PubMed ID: 9685058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.